Neuroglee, a Boston, MA-based provider of personalized evidence-based digital therapeutics (DTx) and virtual care solutions, raised $10M in Series A funding led by OpenSpace Ventures with participation by EDBI.

This funding will help Neuroglee continue to develop its digital therapeutics and virtual clinical services, which combine best-in-class cognitive rehabilitation strategies with remote care management to help patients with mild cognitive impairment due to Alzheimer's disease delay or slow the worsening of symptoms.

Company: Neuroglee Therapeutics

Raised: $10.0M

Round: Series A

Funding Month: September 2021

Lead Investors: OpenSpace Ventures

Additional Investors: EDBI

Company Website: https://www.neuroglee.com/

Software Category: Digital therapeutic platform

About the Company: Neuroglee Therapeutics is a digital therapeutic platform created to treat patients in the early stages of the disease. Neuroglee Therapeutics discovers, develops, and commercializes personalized evidence-based digital therapeutics (DTx) and virtual care solutions to treat and manage patients with neurodegenerative diseases. Neuroglee’s adaptive learning platform uses machine learning and several novel digital biomarkers to dynamically personalize treatment to each patient’s cognitive and physical needs. Treatment includes both therapeutic interventions and evidence-based lifestyle and cognitive behavior therapies tied to cognitive function, mood, and behavior.

Source: https://hitconsultant.net/2021/09/09/neuroglee-dtx-funding/#.YTrEzZ0zbIU